'I'm excited to join this collaborative and experienced team that is applying rigorous science to break new ground in cancer therapy," said Dr. Oravecz. "Deciphering the important interplay between cancer cells and their surrounding environment is an exciting new area of cancer therapeutics. I look forward to leading Parthenon's R&D efforts, and applying new biological insights to pioneer a new and important therapeutic class of medicines to fight cancer."
Dr. Oravecz joins Parthenon from Janssen Biotherapeutics, a division of Johnson & Johnson, where most recently he served as Vice President, Head of Cell Therapy Platform and Discovery. During his tenure at Janssen, he led teams of more than 100 scientists across diverse scientific disciplines to advance new therapeutic candidates in diverse disease areas from discovery into early development and proof of concept studies in humans. Previously, Dr. Oravecz was Executive Director of Biology and Pharmacology at Celgene (acquired by Bristol-Myers Squibb Company) where he was responsible for building a world-class discovery team and contributing to the advancement of several of Celgene's small and large molecule programs. Dr. Oravecz's earlier career included Lexicon Pharmaceuticals, where he served as Vice President of Immunology and Oncology; Novartis Cell and Gene Therapy, where he served as Program Head, HIV Therapy; The National Institutes of Health/U.S. Food and Drug Administration; and The Biological Research Center of the Hungarian Academy of Sciences.
Dr. Oravecz received a M.S. degree in Molecular Biology and a Ph.D. in Immunology from the University of Szeged, Hungary. He completed four fellowships including the Swiss Society for Immunology, the European Association of Immunologists, the British Council, Imperial Cancer Research Fund, and the Fogarty International Center, National Institutes of Health. He is the inventor on eight patents and patent applications and has published nearly 50 research papers and book chapters. About Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information visit parthenontx.com
Contact Information: firstname.lastname@example.org